

Meet The Professors

A case-based discussion on the management of lung cancer in the adjuvant, locally advanced and metastatic settings



EDITOR

Neil Love, MD

FACULTY

F Anthony Greco, MD

Edward S Kim, MD

Thomas J Lynch, MD

Alan B Sandler, MD



Subscribe to Podcasts
or download MP3s
of this program at
MeetTheProfessors.com

from the publishers of

Lung Cancer™
UPDATE



Meet The Professors: A case-based discussion on the management of lung cancer in the adjuvant, locally advanced and metastatic settings

STATEMENT OF NEED/TARGET AUDIENCE

Lung cancer is the leading cause of cancer mortality in the United States in both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been modest, and approximately 85 percent of patients who develop lung cancer will die from it. In addition, a sense of therapeutic nihilism has pervaded the medical community in the past. Chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes. However, recent improvements have been seen in time to progression and survival in lung cancer clinical trials. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. In order to incorporate research advances into developing treatment strategies for patients, the CME program *Meet The Professors* utilizes case-based discussions between community oncologists and clinical investigators.

GLOBAL LEARNING OBJECTIVES

- Critically evaluate the clinical implications of emerging clinical trial data in lung cancer treatment and incorporate these data into management strategies in the adjuvant, neoadjuvant, locally advanced and metastatic settings.
- Counsel appropriately selected patients about the availability of ongoing clinical trials.
- Develop and explain a management strategy for treatment of elderly patients and those with poor performance status in the adjuvant, neoadjuvant, locally advanced and metastatic settings.
- Integrate emerging data on utilization of targeted molecular therapies and molecular and genetic assays in the development of individual management strategies for patients with lung cancer.
- Counsel patients with localized primary lung cancer about the risks and benefits of adjuvant chemotherapy.
- Identify the impact of smoking-related comorbidities on the treatment of patients with lung cancer and integrate smoking cessation into the management strategy for these patients.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the CME information and complete the Evaluation Form located in the back of this book or on our website, MeetTheProfessors.com.

This program is supported by education grants from Genentech BioOncology/OSI Pharmaceuticals Inc and Sanofi-Aventis.

Guide to Audio Program

Compact Disc 1: Tracks 1-7 — case from Dr Ng; Tracks 8-10 — case from Dr Moss; Tracks 11-17 — case from Dr Hoffman; Tracks 18-25 — case from Dr Garrido; **Compact Disc 2:** Tracks 1-13 — case from Dr Harwin; Tracks 14-19 — case from Dr Reeves; Tracks 20-25 — case from Dr Menon; **Compact Disc 3:** Tracks 1-3 — case from Dr Hussein; Tracks 4-7 — case from Dr Weinstein; Tracks 8-11 — case from Dr Seigel; Tracks 12-14 — case from Dr Merchant; Tracks 15-18 — case from Dr Harwin

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process: John Brebner, Karen Green, MD, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lillian Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Greco — Consulting Fees: Bristol-Myers Squibb Company, Eli Lilly and Company; **Contracted Research:** Ascenta Therapeutics, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology. **Dr Kim — Consulting Fees:** AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, ImClone Systems, OSI Pharmaceuticals Inc, Sanofi-Aventis; **Contracted Research:** AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, ImClone Systems, OSI Pharmaceuticals Inc, Sanofi-Aventis; **Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents:** Eli Lilly and Company, Genentech BioOncology, Sanofi-Aventis. **Dr Lynch — Consulting Fees:** AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, Millennium Pharmaceuticals Inc, OSI Pharmaceuticals Inc, Sanofi-Aventis. **Dr Sandler — Contracted Research:** AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Pfizer Inc, Sanofi-Aventis, Wyeth; **Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents:** Genentech BioOncology.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Medical Oncologist Panel

Sara M Garrido, MD
Miami, Florida

William N Harwin, MD
Fort Myers, Florida

Kenneth R Hoffman, MD
Teaneck, New Jersey

Atif M Hussein, MD
Hollywood, Florida

Mohan Menon, MD
New Britain, Connecticut

Noor M Merchant, MD
Sebastian, Florida

Robert A Moss, MD
Fountain Valley, California

Kenneth K Ng, MD
Rockville Centre, New York

William G Reeves, MD
Youngstown, Ohio

Leonard J Seigel, MD
Fort Lauderdale, Florida

Paul L Weinstein, MD
Stamford, Connecticut

MEET THE PROFESSORS DOWNLOADABLE AUDIO

MP3 audio files are available for download on our website www.MeetTheProfessors.com/download-audio

Case Studies

Case 1 from the practice of Kenneth K Ng, MD: A 51-year-old woman, never smoker, diagnosed with Stage IIB NSCLC with two positive lymph nodes. The patient underwent a lobectomy, and an EGFR gene analysis revealed an exon 21 point mutation (presented to Dr F Anthony Greco and Dr Thomas J Lynch).

Case 2 from the practice of Robert A Moss, MD: A 72-year-old man who presented with NSCLC of the upper right lobe and hilum with two brain metastases. The patient underwent gamma knife surgery for the brain lesions and received concurrent chemoradiation therapy with consolidation docetaxel (presented to Dr Greco and Dr Lynch).

Case 3 from the practice of Kenneth R Hoffman, MD: A 73-year-old woman who underwent thoracotomy, which revealed Stage IIIA adenocarcinoma of the left lower lobe with one positive mediastinal lymph node. The patient received four cycles of adjuvant carboplatin/paclitaxel followed by adjuvant radiation therapy and prophylactic cranial irradiation. She was subsequently diagnosed with metastatic disease (presented to Dr Greco and Dr Lynch).

Case 4 from the practice of Sara M Garrido, MD: A 70-year-old woman who presented with a 3-cm lesion in the right upper lobe and a 4.5-cm hilar mass with metastasis to an inguinal lymph node. The patient received six cycles of paclitaxel/carboplatin and bevacizumab with good tumor response and is currently receiving maintenance bevacizumab with no adverse effects (presented to Dr Greco and Dr Lynch).

Case 5 from the practice of William N Harwin, MD: A 49-year-old man with a history of poorly differentiated squamous cell carcinoma of the oropharynx who presented with a right lower lobe mass. After pneumonectomy, pathology showed a 4-cm adenosquamous cell carcinoma with negative margins and three positive lymph nodes. The patient is currently receiving docetaxel/cisplatin chemotherapy (presented to Dr Edward S Kim and Dr Alan B Sandler).

Case 6 from the practice of William G Reeves, MD: An 87-year-old woman, never smoker, diagnosed with squamous cell carcinoma in the right hilar region. A CT scan showed enlarged mediastinal nodes and a bone scan showed thoracic and lumbar metastases. The patient received radiation therapy to the lumbar spine and is currently receiving erlotinib (presented to Dr Kim and Dr Sandler).

Case 7 from the practice of Mohan Menon, MD: A 35-year-old woman who presented with a 5-cm left hilar mass with mediastinal adenopathy on CT/PET scan. The patient received six cycles of carboplatin/docetaxel and radiation therapy. Subsequently, a biopsy revealed metastatic disease to the adrenal gland and the patient underwent a laparoscopic adrenalectomy (presented to Dr Kim and Dr Sandler).

Case 8 from the practice of Atif M Hussein, MD: A 51-year-old man diagnosed with multiple sites of poorly differentiated adenocarcinoma in the lungs, right shoulder area, vertebrae and ribs. The patient received five cycles of paclitaxel/carboplatin and bevacizumab, after which he was diagnosed with liver metastases. The patient then received radiation therapy to his bone lesions, bevacizumab and erlotinib (presented to Dr Kim and Dr Sandler).

Case 9 from the practice of Paul L Weinstein, MD: A 76-year-old man diagnosed with a 3.2-cm squamous cell carcinoma of the left lower lobe with hilar and mediastinal lymphadenopathy. Surgical resection was unsuccessful. The patient received radiation therapy and low-dose weekly carboplatin/docetaxel. The patient is currently enrolled in a clinical trial and was randomly assigned to either erlotinib or placebo (presented to Dr Kim and Dr Sandler).

Case 10 from the practice of Leonard J Seigel, MD: A 69-year-old man shown by CT scan to have an upper right lobe mass. A mediastinoscopy revealed one positive lymph node. The patient received induction chemoradiation therapy followed by surgery (presented to Dr Greco and Dr Lynch).

Case 11 from the practice of Noor M Merchant, MD: A 59-year-old woman who underwent a thoracotomy in July 2006, which revealed a 4.3-cm, moderately differentiated, Grade II NSCLC. The patient received four cycles of adjuvant cisplatin/docetaxel (presented to Dr Greco and Dr Lynch).

Case 12 from the practice of Dr Harwin: A 76-year-old man, never smoker, who presented with numerous bilateral subcentimeter nodules, a right hilar mass and interstitial markings in the right lower lobe. A biopsy revealed poorly differentiated NSCLC. The patient received six cycles of carboplatin/paclitaxel with some response. The disease subsequently progressed, and the patient was treated with gefitinib, resulting in significant tumor response that has been maintained for more than 40 months (presented to Dr Greco and Dr Lynch).

Evaluation Form: *Meet The Professors* Lung Cancer, Issue 1, 2007

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please complete this Evaluation Form. A certificate of completion will be issued upon receipt of your completed Evaluation Form.

Please answer the following questions by circling the appropriate rating:

5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor N/A = Not applicable to this issue of *MTP*

GLOBAL LEARNING OBJECTIVES

To what extent does this issue of *MTP* address the following global learning objectives?

- Critically evaluate the clinical implications of emerging clinical trial data in lung cancer treatment and incorporate these data into management strategies in the adjuvant, neoadjuvant, locally advanced and metastatic settings. 5 4 3 2 1 N/A
- Counsel appropriately selected patients about the availability of ongoing clinical trials.. . . . 5 4 3 2 1 N/A
- Develop and explain a management strategy for treatment of elderly patients and those with poor performance status in the adjuvant, neoadjuvant, locally advanced and metastatic settings.. . . . 5 4 3 2 1 N/A
- Integrate emerging data on utilization of targeted molecular therapies and molecular and genetic assays in the development of individual management strategies for patients with lung cancer. 5 4 3 2 1 N/A
- Counsel patients with localized primary lung cancer about the risks and benefits of adjuvant chemotherapy. 5 4 3 2 1 N/A
- Identify the impact of smoking-related comorbidities on the treatment of patients with lung cancer and integrate smoking cessation into the management strategy for these patients. 5 4 3 2 1 N/A

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter	Effectiveness as an educator
F Anthony Greco, MD	5 4 3 2 1	5 4 3 2 1
Edward S Kim, MD	5 4 3 2 1	5 4 3 2 1
Thomas J Lynch, MD	5 4 3 2 1	5 4 3 2 1
Alan B Sandler, MD	5 4 3 2 1	5 4 3 2 1

OVERALL EFFECTIVENESS OF THE ACTIVITY

- Objectives were related to overall purpose/goal(s) of activity..... 5 4 3 2 1
- Related to my practice needs..... 5 4 3 2 1
- Will influence how I practice 5 4 3 2 1
- Will help me improve patient care 5 4 3 2 1
- Stimulated my intellectual curiosity 5 4 3 2 1
- Overall quality of material 5 4 3 2 1
- Overall, the activity met my expectations..... 5 4 3 2 1
- Avoided commercial bias or influence 5 4 3 2 1

Which of the following audio formats of this program did you use?

- Audio CDs Downloaded MP3s from website

Evaluation Form: *Meet The Professors* Lung Cancer, Issue 1, 2007

REQUEST FOR CREDIT — Please Print Clearly

Name: Specialty:

Degree: MD DO PharmD NP BS RN PA Other

Medical License/ME Number: Last 4 digits of SSN (required):

Street Address:

Box/Suite: City, State, Zip:

Phone Number: Fax Number:

Email:

Research To Practice designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be ____ hour(s).

Signature: Date:

Will the information presented cause you to make any changes in your practice?

Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity.

.....

What other topics would you like to see addressed in future educational programs?

.....

What other faculty would you like to hear interviewed in future educational programs?

.....

Additional comments about this activity:

.....

FOLLOW-UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

Yes, I am willing to participate in a follow-up survey.

No, I am not willing to participate in a follow-up survey.

MTPL107

To obtain a certificate of completion and receive credit for this activity, please fill out the Evaluation Form and fax to (800) 447-4310, or mail to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Evaluation online at www.MeetTheProfessors.com/CME.

Meet The Professors

Editor/CME Director	Neil Love, MD
Managing Editor	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Senior Director, Medical Affairs	Aviva Asnis-Alibozek, PA-C, MPAS
Writers	Lillian Sklaver Poltorack, PharmD Douglas Paley
Continuing Education Administrator for Nursing Content Validation	Sally Bogert, RNC, WHCNP Margaret Peng John Brebner Ginelle Suarez Erin Wall
Director, Creative and Copy Editing Creative Manager Graphic Designers	Aura Herrmann Fernando Rendina Jason Cunniss Tamara Dabney Shantia Daniel Elisa Stambouli
Senior Production Editor Traffic Manager Copy Editors	Alexis Oneca Tere Sosa Dave Amber Margo Harris Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone
Production Manager Audio Production Web Master Contact Information	Rena Chiarelli Frank Cesarano John Ribeiro Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.com Email: CME@ResearchToPractice.com
For CME Information	

Copyright © 2007 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Copyright © 2007 Research To Practice.
This program is supported by education grants from
Genentech BioOncology/OSI Pharmaceuticals Inc and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: October 2007
Release date: October 2007
Expiration date: October 2008
Estimated time to complete: 3.5 hours